Background-The use of upstream small-molecule glycoprotein (GP) IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes (NSTE ACS) has been studied in multiple randomized clinical trials. We systematically reviewed the effect of upstream GP IIb/IIIa inhibitor use in NSTE ACS as reported in published clinical trials. Methods and Results-Randomized clinical trials of upstream small-molecule GP IIb/IIIa inhibitors in NSTE ACS were identified through a PubMed and EMBASE search and were included if they contained 30-day outcome data. Odds ratios were generated from the published data and pooled by means of random effects modeling. The primary outcome measures were 30-day death and 30-day death or myocardial infarction. Primary safety measures were major bleeding and transfusion during the index hospitalization. Twelve clinical trials were included, evaluating tirofiban, eptifibatide, and lamifiban. Of these, 7 evaluated upstream GP IIb/IIIa inhibitors versus placebo (nϭ24 031) and 5 evaluated a strategy of upstream GP IIb/IIIa inhibitors versus upstream placebo with later provisional use at the time of percutaneous coronary intervention (nϭ19 643). Overall, upstream GP IIb/IIIa inhibitor use was associated with an 11% reduction in 30-day death/myocardial infarction (odds ratio [OR], 0.89; 95% confidence interval [CI], 0.83 to 0.95) but no significant mortality effect (OR, 0.93; 95% CI, 0.83 to 1.05). The risk of major bleeding was 23% higher in patients treated with upstream GP IIb/IIIa inhibitors (OR, 1.23; 95% CI, 1.02 to 1.48). Results were similar when only trials comparing upstream GP IIb/IIIa inhibitors versus placebo were considered: 30-day death/myocardial infarction (OR, 0.88; 95% CI, 0.81 to 0.95); 30-day death (OR, 0.89; 95% CI, 0.76 to 1.03); and major bleeding (OR, 1.17; 95% CI, 0.88 to 1.54). Upstream versus selective use at percutaneous coronary intervention trended toward lower 30-day death/myocardial infarction (OR, 0.91; 95% CI, 0.82 to 1.01) but had no effect on mortality (OR, 1.00; 95% CI, 0.81 to 1.23) and increased major bleeding risk by 34% (OR, 1.34; 95% CI, 1.10 to 1.63). Conclusions-In NSTE ACS, treatment with upstream small-molecule GP IIb/IIIa inhibitors provides a significant but modest ischemic benefit when compared with initial placebo. Compared with delayed, selective use at percutaneous coronary intervention, early upstream use is associated with a trend toward fewer ischemic events. However, these modest benefits are associated with an increased risk of bleeding. (Circ Cardiovasc Qual Outcomes. 2011;4:448-458.)
T he last 2 decades have seen major advances in antithrombotic therapy for patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS). One of these has been the development of evidence of benefit through multiple randomized clinical trials for the use of smallmolecule inhibitors of the platelet glycoprotein (GP) IIb/IIIa receptor in the treatment of patients with high-risk NSTE ACS. These randomized clinical trials have formed the evidence base for use of these agents in guidelines recommendations from both the American College of Cardiology/ American Heart Association and the European Society of Cardiology. 1, 2 Despite the number of trials with these agents, their proper placement in the strategy to treat NSTE ACS has been subject to debate, even more so now that alternative antithrombotic therapies have been developed, including different generations of thienopyridines and direct thrombin inhibitors. [3] [4] [5] [6] In addition, major randomized trials of GP IIb/IIIa inhibitors have recently addressed the role of these agents in the treatment of NSTE ACS in the setting of contemporary practice, including the optimal timing of administration in patients undergoing early coronary angiography. 7, 8 We sought to summarize the evidence for use of upstream intravenous small-molecule GP IIb/IIIa inhibitors by performing a systematic overview of published randomized clinical trials in patients with NSTE ACS. The goal of this meta-analysis is to provide an updated comprehensive assessment of efficacy and safety of this class of drugs with the inclusion of recent trials performed in the context of modern treatment of NSTE ACS.
Methods
We used a PubMed and EMBASE search to identify all Englishlanguage, published, randomized clinical trials of upstream smallmolecule GP IIb/IIIa inhibitors in patients presenting with NSTE ACS (Figure 1 ). We refer to upstream as the use of a GP IIb/IIIa inhibitor immediately after random assignment and before a patient underwent a cardiac catheterization by design of the trial. Trials were included if they used initial placebo as a control arm, including trials assessing a strategy of early "upstream" use versus early placebo with delayed provisional use at percutaneous coronary intervention (PCI). The search was done using Boolean logic to find trials including the drugs and disease of interest. Search terms included: "glycoprotein IIb/IIIa inhibitor," "eptifibatide," "tirofiban," "lamifiban," "upstream," "acute coronary syndrome," "unstable angina," and "myocardial infarction." From the search results, trials were excluded if 30-day clinical outcomes of interest were not available or if they evaluated the use of GP IIb/IIIa inhibitors only in patients selected to undergo PCI. Trials with ST-segment elevation-myocardial infarction (MI) patients were not included. Finally, because our focus was on upstream small-molecule GP IIb/IIIa inhibitors and the use of upstream GP IIb/IIIa inhibitors is limited to these agents, trials of upstream abciximab as the investigational drug were excluded. References of the selected publications were reviewed to identify additional articles, and all authors-each an expert in the fieldreviewed the proposed trials for inclusion and were queried to identify potential publications not included in the list. Twelve trials were identified and included in the meta-analysis. A quality assessment of studies included was also performed, using the Delphi criteria. 9
WHAT IS KNOWN
• Over the last 2 decades, the benefits of smallmolecule inhibitors of the platelet glycoprotein (GP) IIb/IIIa receptor in the treatment of patients with high-risk non-ST-segment elevation acute coronary syndromes have been demonstrated in clinical trials, forming the basis for the drugs' inclusion in guideline recommendations from both the American College of Cardiology/American Heart Association and the European Society of Cardiology. • Despite these numerous trials with GP IIb/IIIa inhibitors, their proper placement in the strategy to treat non-ST-segment elevation acute coronary syndromes remains subject to debate, particularly in the context of using multiple antiplatelet agents.
WHAT THE STUDY ADDS
• The results of this meta-analysis of 12 clinical trials demonstrate that the efficacy of upstream GP IIb/IIIa inhibitors has been remarkably consistent over time, despite changes in background therapy, population selection, and strategy for use, but is balanced against consistently higher bleeding. • Pooled results from more recent strategy trials of upstream use versus delayed, selective use at percutaneous coronary intervention that were done in the setting of high clopidogrel use and early invasive management did not show statistically significant reductions in ischemic events with the strategy of upstream GP IIb/IIIa inhibition, although the magnitude of effect seems consistent with prior trials. • A selected strategy of periprocedural use in high-risk patients undergoing percutaneous coronary intervention may optimize the balance of benefit and risk of GP IIb/IIIa inhibitors by targeting patients who will probably benefit most.
Group Definitions
Clinical trials were grouped into 2 patient categories: (1) trials comparing GP IIb/IIIa inhibitor use versus placebo in patients with NSTE ACS and (2) trials in populations for whom an invasive evaluation was planned that compared a strategy of upstream GP IIb/IIIa inhibitor use versus initial placebo with delayed selective GP IIb/IIIa inhibitor use at the time of PCI. Hereafter, the term "upstream" refers to randomized allocation to initiate GP IIb/IIIa inhibitor infusion immediately after enrollment and before diagnostic angiography. "Delayed" refers to the initiation of GP IIb/IIIa inhibitor at the time of PCI. Treatment groups within each trial were categorized according to the initial random assignment: "GP IIb/IIIa inhibitor" if the initial treatment assignment was to receive a GP IIb/IIIa inhibitor (regardless of dose used), concomitant therapy (eg, heparin), or whether crossover to active therapy was allowed selectively at the time of PCI; and "placebo" if the initial random assignment was to placebo, regardless of whether crossover to active therapy was allowed at PCI.
Efficacy and Safety End Points
The primary efficacy end point for the meta-analysis was the composite of death or MI at 30 days, a conventionally accepted time
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point to assess efficacy of acute therapies in patients with ACS. We also examined 30-day mortality. Ischemic end points were used as defined by and reported in the publication for each trial; no attempts were made to reclassify events. The primary safety measures included major bleeding during the index hospitalization and transfusion. As with MI, we used major bleeding as determined for and reported by each trial. The classification of major bleeding used in clinical trials has not been consistent. 10 The most consistently reported classification across trials was the Thrombolysis In Myocardial Infarction (TIMI) bleeding scale (used in 7 trials, including 35 178 patients; 81% of the entire cohort). Therefore, we used the TIMI bleeding classification as the major bleeding end point for all trials reporting TIMI bleeding. For the remaining trials not reporting TIMI bleeding, we retained the trial-specific definition of major bleeding. Nonmajor bleeding was also reported and analyzed according to the TIMI scale (ie, TIMI minor bleeding) in the trials reporting this classification and using the trial-specific definition in the remainder. Because of the inconsistency in reporting of major bleeding, transfusion was also analyzed as a safety outcome as an indirect but objective indicator of clinically relevant bleeding.
Data Analysis
We obtained the raw number of patients having the outcomes of interest among all patients in each randomized treatment group from each of the publications of the selected clinical trials. When necessary, we accessed the trial databases to obtain data concerning the outcomes of interest if those were not shown in the main publication.
Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated by use of Fast*Pro software for the GP IIb/IIIa inhibitor versus placebo comparison in each randomized clinical trial. The ORs for individual trials were combined assuming an empirical Bayesian model described by Hedges and Olkin. 11 The empirical Bayesian random-effects model reduces to a fixed-effects model when the studies are homogeneous. The method accommodated heterogeneity by assuming that the true effect differed among studies and therefore must be represented by a distribution of values instead of a single value. The result was a wider range of uncertainty about the point estimate than was calculated with fixed-effects models.
Although the random-effects model accommodated variability among studies, the extent of heterogeneity in the trials was examined. The Q statistic of DerSimonian and Laird approximated a 2 statistic to test a null hypothesis that all of the studies estimated the same true value. 12 The Begg and Mazumdar rank correlation was used to assess asymmetry of the funnel plot.
We calculated an overall OR (95% CI) for all 12 trials and generated combined ORs separately in the 2 groups of trials described above to provide a summary of efficacy and safety of initial upstream small-molecule GP IIb/IIIa inhibitor versus initial placebo with selective use at the time of PCI in patients with NSTE ACS distinct from that for the placebo-controlled trials.
Results

Clinical Trials
We identified 12 randomized clinical trials for inclusion in the meta-analysis. 7, 8, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] The main features of each trial are reported in Table 1 . Treatment in all trials was on a background of aspirin therapy. The trials were published from 1996 to 2009 and evaluated a total of 43 674 patients with NSTE ACS. Seven trials compared upstream small-molecule GP IIb/IIIa inhibitors versus placebo only (nϭ24 031). Of these, 1 trial evaluated eptifibatide, 17 3 studied lamifiban, 13, 16, 18 and 3 assessed tirofiban. 14, 15, 19 Five trials evaluated upstream GP IIb/IIIa inhibitor versus selective delayed GP IIb/IIIa inhibitor use at the time of PCI in patients for whom an invasive assessment was planned (nϭ19 643). The design of those trials was such that patients initially received either a GP IIb/IIIa inhibitor infusion or placebo, and then at the time of PCI could be crossed over to active therapy with a GP IIb/IIIa inhibitor according to the preference of the treating physician or as indicated by the trial design. The study drug was eptifibatide in 2 trials, 7,22 tirofiban in 2, 20,21 and in 1 trial, the decision of which GP IIb/IIIa inhibitor to use (tirofiban or eptifibatide) was determined by the treating physician. 8 In the EARLY ACS trial, a double-bolus regimen of eptifibatide, was used. The use of thienopyridine pretreatment is reported in trials published since 2006; thus, trials in which most patients were pretreated with thienopyridines are, with no exceptions, those allowing crossover at the time of PCI. 7,8,20 -22 Concerning the quality assessment, 8 of the 12 studies included scored 9 of 9, 1 scored 6 (because of open-label design), and 3 had scores Ͻ6. Finally, the funnel plot indicated no evidence of publication bias (Pϭ0.21).
Efficacy Results
Overall, the use of initial GP IIb/IIIa inhibitor compared with initial placebo was associated with a significant (OR, 0.89; 95% CI, 0.83 to 0.95) reduction in the odds of death or MI at 30 days ( Figure 2 ). The estimate of the effect was consistent in the trials designed against placebo, without later crossover at PCI (OR, 0.88; 95% CI, 0.81 to 0.95) and in those allowing the selective use of GP IIb/IIIa inhibitors at PCI (OR, 0.91; 95% CI, 0.82 to 1.01), but was not statistically significant in the latter. There was no significant heterogeneity across trials (Pϭ0.77). Mortality rate was lower but not statistically different among patients randomly assigned to GP IIb/IIIa inhibitors in trials against placebo (OR, 0.89; 95% CI, 0.76 to 1.03) and was neutral in trials allowing peri-PCI use (OR, 1.00; 95% CI, 0.81 to 1.23), resulting in no significant differences in the combined result of all trials (OR 0.93; 95% CI 0.83 to 1.05) ( 
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IIb/IIIa inhibitor studied in phase III that is not available in practice) from the analysis did not modify the results (30-day death or MI: OR, 0.89, 95% CI, 0.83 to 0.95). A sensitivity analysis that did not include studies with lower-quality scores confirmed our findings.
Safety Results
GP IIb/IIIa inhibitors increased the risk of major and nonmajor bleeding and red blood cell transfusion ( 
Discussion
The upstream use of intravenously administered, smallmolecule GP IIb/IIIa inhibitors in patients with NSTE ACS overall reduces the risk of death or MI through 30 days by 11% compared with initial placebo. Results were consistent when placebo-controlled trials and trials allowing crossover to active therapy at the time of PCI were considered separately, with a trend toward benefit of a similar magnitude for routine upstream use compared with a strategy of selective use at the time of PCI among patients intended for an invasive evaluation. Mortality alone at 30 days was not significantly affected by treatment. Counterbalancing these modest efficacy benefits was a 23% increase in major bleeding and 27% increase in transfusion with the administration of GP IIb/IIIa inhibitors. More than 43 000 patients have been enrolled in trials assessing the efficacy and safety of small-molecule GP IIb/IIIa inhibitors in patients with NSTE ACS, which became a class I guideline recommendation for the treatment of patients with high-risk NSTE ACS. 23 However, many ques-tions about the use of GP IIb/IIIa inhibitors remained. First, in unselected populations with NSTE ACS not routinely undergoing PCI, the benefit of GP IIb/IIIa inhibitors was modest. 24 Subgroups of patients with positive troponin or diabetes appeared to have enhanced benefit from this class of drugs, [25] [26] [27] and trials of GP IIb/IIIa inhibitors used in patients scheduled for PCI showed a greater magnitude of ischemic benefit than that observed in trials of patients with NSTE ACS. 28, 29 This led to debate as to whether GP IIb/IIIa inhibitors should be selectively used only in high-risk NSTE ACS patients for whom a decision to perform PCI had been made rather than initiating therapy at the time of initial diagnosis with NSTE ACS. 30, 31 All of these issues resulted in equipoise surrounding the use of upstream GP IIb/IIIa inhibitors in NSTE ACS, which has been reflected in their inconsistent use in clinical practice and a nearly equal use of upstream versus periprocedural strategy. 32, 33 In the decade after the publication of the first GP IIb/IIIa inhibitor trials and the related guidelines recommendations, treatment of NSTE ACS changed rapidly with more routine use of an early coronary angiography and the use of dual oral antiplatelet therapy with aspirin and clopidogrel. 1 Finally, there has been increasing awareness of the clinical relevance of bleeding and a new focus on the balance of efficacy and safety of antithrombotic medications. 34, 35 These changes necessitated a reevaluation of the role of GP IIb/IIIa inhibitors in the setting of contemporary ACS care. Two large, randomized clinical trials and 3 smaller ones have now assessed the safety and efficacy of upstream GP IIb/IIIa inhibitors in patients routinely undergoing an early invasive strategy and largely on the background of dual antiplatelet therapy. 7,8,20 -22 An important feature of these trials has been that patients in the placebo group were allowed to selectively receive GP IIb/IIIa inhibitors when PCI was performed. 
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Our results demonstrate that the use of GP IIb/IIIa inhibitors compared with placebo, with or without the use of selective treatment at the time of PCI, is associated with a significant yet modest 11% reduction of 30-day death or MI. Interestingly, the effect on 30-day ischemic outcomes observed in the 5 trials of a strategy of upstream use in patients with planned invasive evaluation versus a strategy of initial placebo with delayed, selective use at PCI were consistent in magnitude and direction with the pooled results for the 7 trials with a GP IIb/IIIa inhibitor versus "pure" placebo (ie, no delayed, peri-PCI use allowed in the placebo group), and no heterogeneity was found. Of note, the latter trials were performed in the presence of less routine invasive evaluation and before the availability of clopidogrel and other modern secondary prevention treatments.
Although crossover from placebo to active GP IIb/IIIa inhibitor treatment was allowed by design in the EARLY ACS and ACUITY trials, only 23% of EARLY ACS patients and 55% of ACUITY patients who were randomly assigned to initial placebo plus selective GP IIb/IIIa inhibitor use at PCI received a GP IIb/IIIa inhibitor. 7, 8 Hence, the comparison was largely one of GP IIb/IIIa inhibitor versus placebo as the comparator group and may explain the similarity in the magnitude of the treatment effect observed between the timing of administration strategy trials and the "pure" placebo trials. This hypothesis is supported by the observation that there was a gradient in the point estimate of the OR for treatment benefit of upstream GP IIb/IIIa inhibitor use from 0.95 in ACUITY, in which 55% of patients overall converged to active treatment (94% in PCI patients), to 0.89 in EARLY ACS, in which 23% of the initial placebo group switched to active treatment (39% in PCI patients). It also suggests less relevance of timing of administration to the effect of the drug, as the point estimate of the OR for ischemic events tends to neutral with increased peri-PCI use. In addition, it must be considered that these more recent trials selected patients for whom an invasive evaluation was planned. To the extent that there is an enhanced benefit of GP IIb/IIIa inhibitors in invasively treated patients, selecting a trial population for use of invasive management may have offset changes in practice and crossover in the placebo group to yield an overall treatment effect similar to that in "pure placebo," controlled trials with less intervention. The use of a double-bolus regimen of eptifibatide in the EARLY ACS trial did not result in an apparent clinical advantage of upstream treatment. 7 Pretreatment with clopidogrel was widely used in the most recent trials. 7,8,20 -22 Background dual antiplatelet treatment in the placebo group could have potentially reduced the observed benefit of GP IIb/IIIa inhibitors for ischemia events in these trials compared with studies in which patients received only aspirin. However, as already noted, the results of earlier trials with no clopidogrel use were consistent with the results Major bleeding rates are displayed and analyzed according to the TIMI classification (ie, TIMI major) for the trials for which this information was available. When TIMI classification was not available, the trial-specific definition of major bleeding was retained. TIMI classification is reported for the following trials: PRISM, PRISM PLUS, PURSUIT, Kim, PRACTICE, ACUITY Timing, and EARLY ACS (35 178 patients, 81% of the entire cohort). Likewise, nonmajor bleeding is reported using the TIMI scale (ie, TIMI minor bleeding) when available or retaining the trial-specific classification when bleeding was not classified by TIMI definition.
*In PRISM-PLUS, transfusion data were available in 644 patients in the tirofiban group and 341 in the placebo group.
of more recent trials with higher clopidogrel use, and although a small decline in the estimated efficacy of the GP IIb/IIIa inhibitor was empirically observed, there was no significant heterogeneity among trials. In addition, analysis from individual trials indicated no significant change in the efficacy of upstream GP IIb/IIIa inhibitors according to early clopidogrel use and no significant interaction. 7, 8 The modest benefits observed in NSTE ACS patients treated with GP IIb/IIIa inhibitors must be put into the context of the safety of this class of drugs. We estimated that GP IIb/IIIa inhibitor use increased the risk of major bleeding and the risk of transfusion by approximately 25%. The risk of bleeding with routine upstream GP IIb/IIIa inhibitor use appeared to be greater in populations treated with an early invasive strategy and with increased use of clopidogrel (ie, triple antiplatelet therapy). The relative value of preventing an ischemic event versus causing a bleeding event with the use of antithrombotic drugs is still debated, and an accepted formula to trade off efficacy versus bleeding (ie, how many bleeding events equal 1 MI) has yet to be established. The unfavorable consequences of bleeding are well demonstrated 36 ; however, the official view of the Food and Drug Administration is that nonfatal MI represents "irreversible tissue damage"; therefore, the "benefit of preventing such events is generally worth the risk of bleeding events that have no irreversible consequences." 37 In this regard, until more empirical evidence is available to allow systematic appraisal of the benefit-risk trade-off in antithrombotic therapy, both ischemic and bleeding risk should be assessed in selecting patients for treatment with these agents to reduce ischemic events and minimize bleeding. 38 -41 Thus, the balance between reduction in ischemic events and risk of bleeding observed in the meta-analysis supports shifting the use of these agents away from routine upstream use, with pre-PCI use reserved for situations in which ischemic risk clearly outweighs the risk of major bleeding.
Mortality rates were low in the trials examined. Thus, any potential treatment effect on death is likely small and not possible to identify precisely even with the large sample size available for this analysis. It is possible that the effects of GP IIb/IIIa inhibitors on MI and bleeding may counterbalance each other on mortality, although it is extremely difficult to disentangle these relationships.
Our results point to the need to tailor this class of drugs to patients in whom the efficacy/risk balance is most favorable. From this point of view, the use of GP IIb/IIIa inhibitors in the catheterization laboratory in high-risk patients undergoing PCI remains a viable strategy supported by strong evidence. 28 In addition, beyond the existing alternatives to upstream GP IIb/IIIa inhibitors, new treatments are becoming available. 5, 6 Considering these observations in aggregate, the use of routine upstream GP IIb/IIIa inhibitors in NSTE ACS is likely to become limited to patients likely to undergo PCI and who are at high risk of ischemic complications and low risk of bleeding, although identification of these individuals warrants further study moving toward the development of stratified medicine.
Limitations
Trials included were conducted during several years and were subject to practice changes, particularly related to use of PCI and thienopyridines. The definition of MI used was not identical among trials. Although statistical tests for heterogeneity were negative for ischemic end points, one cannot rule out that differences across studies may have influenced the results. Nonetheless, stratification by study type showed consistent results. Because the design of this study was aimed to provide estimates of effects of GP IIb/IIIa inhibitors, we have not provided data by subgroups. Specifically, patientlevel analyses investigating the effects of concomitant use of thienopyridines and PCI may be helpful to further define the role of upstream GP IIb/IIIa inhibitors in modern treatment of ACS. Furthermore, patient-level data may be helpful to perform modeling to identify subsets of patients with more favorable efficacy versus safety profiles. However, these analyses are complex, and many will be subject to biases related to postrandomization treatment decisions. The duration of follow-up was only up to 30 days, but this is a conventionally established time point at which to evaluate the effect of acute treatments in ACS. The definition of bleeding used across trials was not consistent, and we found significant heterogeneity on major and nonmajor bleeding. To obviate this, we included transfusion as a more objectively quantifiable bleeding measure.
Conclusion
The efficacy of upstream GP IIb/IIIa inhibitors has been remarkably consistent over time, despite changes in background therapy, population selection, and strategy for use, but is balanced against consistently higher bleeding. Pooled results from more recent strategy trials of upstream use versus delayed, selective use at PCI did not show statistically significant reductions in ischemic events with the strategy of upstream GP IIb/IIIa inhibition. A selected strategy of periprocedural use in high-risk patients undergoing PCI may optimize the balance of benefit and risk of GP IIb/IIIa inhibitors by targeting patients who will probably benefit most. 
